#119929
Re: Farmas USA
dejo el mensual de SPY tal y como lo veo … toma velica de casi -10%
Por cierto RSI diario en 27 … se adentra en sobreventa
Por cierto RSI diario en 27 … se adentra en sobreventa
Our Take
Amarin reported impressive results with both fourth-quarter earnings and revenues beating estimates. Moreover, sales of Vascepa continued on its strong growth path. The projected sales growth for 2020 also indicates growth trend to continue. U.S. label expansion, Canadian approval and improved payer coverage for Vascepa as well as increased sales force support the strong outlook. The company believes Vascepa has multi-billion dollar potential.
Meanwhile, discontinuation of a CVOT study by AstraZeneca (AZN - Free Report) last month on Epanova, an omega-3 based drug like Vascepa and a possible strong competitor, further boosts Vascepa's prospects.